Bilirubin as a Surrogate Marker for Atazanavir in Children

May/June 2013

Findings for a study looking at paediatric atazanavir dosing and plasma bilirubin as a possible surrogate for atazanavir therapeutic drug monitoring (TDM) were presented at the 14th International Workshop on Clinical Pharmacology.

Although atazanavir dose is not predictive of Cmin, bilirubin might be a surrogate marker for atazanavir Cmin in this population.

TDM data of atazananvir from children and adolescents <18 years from a Canadian cohort were analysed. Atazanavir Cmin were estimated using a half-life of 10.10 and 5.58 hours with and without ritonavir boosting respectively, for levels taken more than 4 hours post-dose. Cmin below 0.15 was considered subtherapeutic. The investigators evaluated associations between dose Cmin and bilirubin Cmin.

Data from 15 participants and 35 TDMs were included in the analysis; the majority (93%) was black and 67% were girls. Their median age was 15 years (range 8-18), weight 49 kg (range 29-74) and body surface area 1.47 m2 (range 1.00-1.88). The median atazanavir dose was 4.42 mg/kg (range 3.40-10.49) and 150 mg/m2 (range 125-299); most (74%) doses were boosted with ritonavir.

The median Cmin for TDMs for participants receiving unboosted atazanavir (n=5) was 0.05 mg/L (range 0-0.25); 60% of these were in the subtherapeutic range. For those receiving boosted atazanavir (n=19), median Cmin was 0.79 mg/L (range 0-1.85), 11% subtherapeutic. Cmin could not be evaluated in 11 TDMs.

The investigators found no association between Cmin and dose: mg/kg, p=0.81 and mg/m2, p=0.75; this remained similar after adjustment for ritonavir use. They found bilirubin concentrations of 18 ug/L to be predictive of Cmin > 0.15 mg/L with 95% sensitivity and 80% specificity, AUC 0.91 (95% CI 0.76-1.00). They noted that the results need to be confirmed in prospective studies.


Wong A et al. Biliruben as a surrogate marker for atazanavir concentrations in a pediatric population. 14th International Workshop on Clinical Pharmacology. 22-24 April 2013. Amsterdam. Poster abstract P_14.

This article was provided by HIV i-Base. It is a part of the publication HIV Treatment Bulletin. Visit HIV i-Base's website to find out more about their activities, publications and services.

No comments have been made.

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read's Comment Policy.)

Your Name:

Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:


The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.